For the third quarter of fiscal year 2023, ADAPTIMMUNE THERAPEUTICS ($NASDAQ:ADAP) reported total revenue of USD 7.3 million, a 4.4% increase from the same period in the prior year. Net income for the quarter was USD -45.6 million, an increase from last year’s figure of -41.4 million. The quarter ended on September 30 2023.
Analysis – Adaptimmune Therapeutics Stock Fair Value Calculation
GoodWhale’s analysis of ADAPTIMMUNE THERAPEUTICS’s fundamentals has revealed that the company’s intrinsic value is estimated to be around $19.8, as calculated by our proprietary Valuation Line. This means that the current stock price of $0.6 is undervalued by a whopping 97.0%. This indicates that ADAPTIMMUNE THERAPEUTICS shares have huge potential for growth. Our analysts strongly believe that ADAPTIMMUNE THERAPEUTICS is a great long-term investment option. More…
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Adaptimmune Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Adaptimmune Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Adaptimmune Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Adaptimmune Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company’s T-cell therapy platform harnesses the body’s own immune system to target and kill cancer cells. Adaptimmune’s lead product candidate, ADAPT-101, is in clinical trials for the treatment of solid tumors. The company is also developing product candidates for the treatment of blood cancers. Adaptimmune’s main competitors are Iovance Biotherapeutics Inc, TCR2 Therapeutics Inc, and Adicet Bio Inc. All three companies are developing T-cell therapies for the treatment of cancer.
– Iovance Biotherapeutics Inc ($NASDAQ:IOVA)
Iovance Biotherapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of cancer immunotherapy products. The company has a market cap of 1.24B as of 2022 and a Return on Equity of -56.45%. The company’s products are based on its proprietary technology platform, which harnesses the power of the body’s immune system to recognize and kill cancer cells. Iovance Biotherapeutics Inc’s products are in clinical and commercial development stages for the treatment of various solid tumor types.
– TCR2 Therapeutics Inc ($NASDAQ:TCRR)
The company’s market cap is 49.48 million as of 2022, a return on equity of -24.78%. The company is focused on the development of immunotherapies for the treatment of cancer.
Adicet Bio Inc is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.
Adicet Bio Inc has a market cap of 836.46M as of 2022, a Return on Equity of -9.85%. Adicet Bio is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.
Adaptimmune Therapeutics reported total revenue of USD 7.3 million in the third quarter of fiscal year 2023, a 4.4% increase from the same period a year ago. Net income for the quarter was negative at USD -45.6 million, an improvement from the -41.4 million figure the year before. Despite this, the stock price dropped on the same day, suggesting that investors are not optimistic about the company’s performance. In light of this, investors considering Adaptimmune should conduct further research into the company’s financials and operations before investing.